Summary of Option Care Health Q1 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $1.4 billion, up 1% year-over-year, but below expectations.

Adjusted EBITDA: $105 million, down 6% from the prior year, in line with expectations.

Adjusted EPS: $0.40, flat compared to the previous year, with a $0.02 uplift from share repurchases.

Gross Profit: Slight decline due to lower chronic therapy revenue; a revised estimate for gross profit headwind from the Chronic Inflammatory Disease (CID) portfolio is now $55 million, up from a prior estimate of $25-$35 million.

Operating Cash Flow: A usage of $12 million, consistent with seasonal expectations.

Net Debt to Leverage Ratio: 2.2x, with an expanded revolving credit facility from $400 million to $850 million.

2Strategic Updates and Business Highlights

Acute Therapy Growth: High single-digit growth driven by strong execution and partnerships with hospitals and health systems.

Chronic Therapy Challenges: A slight decline in revenue attributed to unexpected patient census resets and therapy mix issues, particularly affecting the CID portfolio.

Patient Satisfaction: Consistently high patient satisfaction scores in the low 90s and Net Promoter Scores in the mid-70s.

Ambulatory Infusion Clinics: Increased utilization with a 14% year-over-year growth in visits, now operating in 28 locations.

Commercial Strategy: Plans to enhance commercial capabilities, including increasing the size of the commercial team and refining the go-to-market model.

3Forward Guidance and Outlook

Revenue Guidance: Adjusted to a range of $5.675 billion to $5.775 billion for the full year, reflecting a negative 600 basis point headwind primarily due to CID portfolio issues.

EBITDA Guidance: Maintained at $480 million to $505 million, with a projected growth of 5% to 9%.

Operating Cash Flow Target: Adjusted to at least $320 million, considering lower revenue expectations.

Second Quarter Expectations: Anticipated mid-single-digit revenue growth and high single-digit EBITDA growth sequentially from Q1.

4Bad News, Challenges, or Points of Concern

Revenue Growth: Overall revenue growth of only 1% did not meet expectations, with chronic therapy revenue declining and acute therapy growth being the only bright spot.

CID Portfolio Issues: Significant headwinds from the CID portfolio, particularly related to patient retention and unfavorable therapy mix, leading to a revised outlook.

Competitive Pressures: Increased competition in the market, with some patients lost to competitors due to changes in health plans and formulary management.

Administrative Delays: Increased patient benefit reverification and authorization processes led to elongated approval timelines, impacting patient transitions and retention.

5Notable Q&A Insights

Patient Loss: Management acknowledged losing patients to competitors, particularly due to the transition of Stelara patients to alternative therapies.

Visibility and Confidence: There is confidence that the reset in patient census is a one-time event, and the company expects to rebuild its patient base moving forward.

Cost Management: Discussions highlighted ongoing efforts to manage costs, including potential reductions in variable compensation and a focus on maximizing gross profit from acute therapies.

Long-term Growth Outlook: Despite current challenges, management expressed confidence in returning to a growth trajectory, emphasizing the importance of execution and strategic investments. Overall, while Option Care Health faces significant challenges in its chronic therapy portfolio and competitive landscape, it maintains a focus on strategic growth initiatives and operational excellence to navigate these headwinds.